Lucio Laudadio

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience

Patrizia Vici, Laura Pizzuti, Andrea Michelotti et al. · Oncotarget · 2017 · 70 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial

Lucia Del Mastro, Francesca Poggio, Eva Blondeaux et al. · The Lancet Oncology · 2022 · 50 citations

Medicine, Oncology, Pharmacology +12

Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey

Nicola Tinari, Caterina Fanizza, Marilena Romero et al. · Clinical Breast Cancer · 2014 · 34 citations · Full text

Medicine, Oncology, Breast Oncology +9

Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer

Luigi Di Lauro, Patrizia Vici, Pietro Del Medico et al. · Breast Cancer Research and Treatment · 2013 · 34 citations

Medicine, Endocrinology, Oncology +14